Literature DB >> 25769061

Muscle wasting in cancer: the role of mitochondria.

Josep M Argilés1, Francisco J López-Soriano, Silvia Busquets.   

Abstract

PURPOSE OF REVIEW: The aim of the present review is to examine the impact of mitochondrial dysfunction in cancer cachexia. RECENT
FINDINGS: Oxidative pathways are altered in this tissue during muscle wasting and this seems to be a consequence of mitochondrial abnormalities that include altered morphology and function, decreased ATP synthesis and uncoupling.
SUMMARY: An alteration of energy balance is the immediate cause of cachexia. Both alterations in energy intake and expenditure are responsible for the wasting syndrome associated with different types of pathological conditions, such as cancer. Different types of molecular mechanisms contribute to energy expenditure and, therefore, involuntary body weight loss, one of which is mitochondrial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25769061     DOI: 10.1097/MCO.0000000000000164

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  32 in total

Review 1.  Neural Control of Energy Expenditure.

Authors:  Heike Münzberg; Emily Qualls-Creekmore; Hans-Rudolf Berthoud; Christopher D Morrison; Sangho Yu
Journal:  Handb Exp Pharmacol       Date:  2016

Review 2.  The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting.

Authors:  James A Carson; Justin P Hardee; Brandon N VanderVeen
Journal:  Semin Cell Dev Biol       Date:  2015-12-01       Impact factor: 7.727

3.  Sarcopenia in resected non-small cell lung cancer: let's move to patient-directed strategies.

Authors:  Philippe Icard; Antonio Iannelli; Hubert Lincet; Marco Alifano
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Colon 26 adenocarcinoma (C26)-induced cancer cachexia impairs skeletal muscle mitochondrial function and content.

Authors:  Daria Neyroud; Rachel L Nosacka; Andrew R Judge; Russell T Hepple
Journal:  J Muscle Res Cell Motil       Date:  2019-04-03       Impact factor: 2.698

5.  Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting.

Authors:  Hawley E Kunz; Jessica M Dorschner; Taylor E Berent; Thomas Meyer; Xuewei Wang; Aminah Jatoi; Rajiv Kumar; Ian R Lanza
Journal:  J Biol Chem       Date:  2020-10-01       Impact factor: 5.157

6.  Voluntary exercise does not improve muscular properties or functional capacity during C26-induced cancer cachexia in mice.

Authors:  Charlotte Hiroux; Sebastiaan Dalle; Katrien Koppo; Peter Hespel
Journal:  J Muscle Res Cell Motil       Date:  2021-02-19       Impact factor: 2.698

Review 7.  Exosomal microRNAs in cancer-related sarcopenia: Tumor-derived exosomal microRNAs in muscle atrophy.

Authors:  Chenyuan Li; Qi Wu; Zhiyu Li; Zhong Wang; Yi Tu; Chuang Chen; Si Sun; Shengrong Sun
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-07

8.  Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting.

Authors:  Hawley E Kunz; Jessica M Dorschner; Taylor E Berent; Thomas Meyer; Xuewei Wang; Aminah Jatoi; Rajiv Kumar; Ian R Lanza
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

9.  Pectoralis major muscle atrophy is associated with mitochondrial energy wasting in cachectic patients with gastrointestinal cancer.

Authors:  Adeline Dolly; Thierry Lecomte; Nicolas Tabchouri; Morgane Caulet; Nicolas Michot; Benjamin Anon; Romain Chautard; Yoann Desvignes; Mehdi Ouaissi; Gaëlle Fromont-Hankard; Jean-François Dumas; Stéphane Servais
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-03-22       Impact factor: 12.063

10.  Pharmacological or genetic inhibition of iNOS prevents cachexia-mediated muscle wasting and its associated metabolism defects.

Authors:  Jason Sadek; Derek T Hall; Bianca Colalillo; Amr Omer; Anne-Marie K Tremblay; Virginie Sanguin-Gendreau; William Muller; Sergio Di Marco; Marco Emilio Bianchi; Imed-Eddine Gallouzi
Journal:  EMBO Mol Med       Date:  2021-06-07       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.